# 4D Molecular Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/4d-molecular-therapeutics

- Industry: Biotechnology
- Headquarters: Emeryville, US
- Website: www.4dmoleculartherapeutics.com
- Total disclosed funding: $165M
- Latest round: Series C (Jun 16, 2020)
- Investors on record: 20

## About

Founded in 2013 and based in California, US, 4D Molecular Therapeutics LLC operates as a biotechnology company that focuses on developing gene therapeutics for the treatment of lysosomal storage diseases, lung diseases, muscular dystrophies, and ophthalmic diseases.

## Funding rounds

- Series C, Jun 16, 2020, $75M — Pappas Capital, Octagon Asset Management, Viking Global Investors, ArrowMark Partners, Pfizer Venture Investments, Cystic Fibrosis Foundation, Casdin Capital, BVF Partners, Chiesi Ventures, Perceptive Advisors, Mirae Asset Venture Investment, Ridgeback Asset Management, Berkeley Catalyst Fund, QUAD Ventures, Longevity Vision Holding, Amzak Capital Management
- Series B, Aug 27, 2018, $90M — Pappas Capital, Viking Global Investors, ArrowMark Partners, Pfizer Venture Investments, BVF Partners, Janus Henderson Investors, Ridgeback Capital Management, Chiesi Ventures, Perceptive Advisors, Mirae Asset Financial Group, Berkeley Catalyst Fund, CureDuchenne Ventures

## Investors

- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series B, Series C
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B, Series C
- ArrowMark Partners — Series B, Series C
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B, Series C
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B, Series C
- Janus Henderson Investors — Series B
- Ridgeback Capital Management — Series B
- Chiesi Ventures (https://capitalatlas.ai/funds/chiesi-ventures) — Series B, Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B, Series C
- Mirae Asset Financial Group — Series B
- Berkeley Catalyst Fund (https://capitalatlas.ai/funds/berkeley-catalyst-fund) — Series B, Series C
- CureDuchenne Ventures (https://capitalatlas.ai/funds/cureduchenne-ventures) — Series B
- Octagon Asset Management (https://capitalatlas.ai/funds/octagon-asset-management) — Series C
- Cystic Fibrosis Foundation — Series C
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series C
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series C
- Ridgeback Asset Management — Series C
- QUAD Ventures (https://capitalatlas.ai/funds/quad-ventures) — Series C
- Longevity Vision Holding (https://capitalatlas.ai/funds/longevity-vision-holding) — Series C
- Amzak Capital Management (https://capitalatlas.ai/funds/amzak-capital-management) — Series C